TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04242667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health (web-based) disclosure portal
Description: Patient uses secure web-based portal to access genetic research results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health (web-based) disclosure portal
Description: Patient uses secure web-based portal to access genetic research results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider mediated disclosure
Description: Patient has disclosure of genetic research result by a provider (genetic counselor)
Study: NCT02412852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
Study: NCT00868374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Study: NCT03352518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4NR
Description: The investigational medical device will collect spectral raman data from tissue.
Study: NCT02002754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bambuterol Hydrochloride tablets
Description: Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bambuterol Hydrochloride tablets
Description: Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Study: NCT01205425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCI on the basis of coronary angiography
Description: Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT guided PCI
Description: The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
Study: NCT01289262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure technique
Description: Uterine incision will be closed with purse string closure technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously locked closure technique
Description: Uterine incision will be closed with continuously locked closure technique
Study: NCT00850746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM443
Description: Oral
Study: NCT02364063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urotherapy with or without pharmacotherapy
Description: Individualized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urotherapy with or without pharmacotherapy
Description: Individualized
Study: NCT04242667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider mediated disclosure
Description: Patient has disclosure of genetic research result by a provider (genetic counselor)
Study: NCT03086187

Intervention type: DEVICE
Group type: OTHER
Intervention: Hephaistos unloading orthosis
Description: The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
Study: NCT00074698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm description.
Study: NCT00910624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
Study: NCT00850746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM443
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral
Study: NCT02519881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: simple microfracture of ankle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: simple microfracture of ankle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartiFill
Description: add collagen when doing microfracture
Study: NCT01587742

Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.

Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.

Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.

Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.

Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
Study: NCT02914509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT00552110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
Description: MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
Description: MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
Study: NCT04176094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16h overnight duty
Description: schedule observed by participating ICUs.
Study: NCT00552110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS) once daily
Description: MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline nasal spray (OXY) twice daily
Description: OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MFNS given every morning and every evening x 2 weeks.
Study: NCT03602560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar 5-10 mg
Description: Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
Study: NCT00427856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: Obatoclax mesylate 40mg, and 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: Obatoclax mesylate 40mg, and 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab
Study: NCT02096094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardization phase
Description: Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardization phase
Description: Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control bath
Description: Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
Study: NCT04176094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24h overnight duty
Description: schedule observed by participating ICUs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handover training
Description: Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handover training
Description: Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
Study: NCT01695720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VisionScope Imaging (VSI) Exam
Description: The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
Study: NCT01469026

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT or Conventional diagnostics including CT
Description: Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT or Conventional diagnostics including CT
Description: Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml).
Study: NCT01561807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03148808

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NVS Therapy
Description: Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
Study: NCT03549364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Race
Description: 1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
Study: NCT01307722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left atrial distensibility-guiding prescription of heart failure drugs
Description: This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
Study: NCT01889719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: injections of MVA-CMDR vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-CMDR
Description: injections of MVA-CMDR vaccine
Study: NCT00627419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
Study: NCT03048812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O'Ring Attachment (A)
Description: Attachment A will be inserted in three months of follow up,followed by treatment B in a random order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O'Ring Attachment (A)
Description: Attachment A will be inserted in three months of follow up,followed by treatment B in a random order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equator Attachment (B)
Description: Attachment B will be inserted in three months of follow up,followed by treatment A in a random order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equator Attachment (B)
Description: Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
Study: NCT03600376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ryanodex and Standard of Care
Description: Ryanodex to be administered as a rapid IV push

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Body cooling measures and supportive measures
Study: NCT00415363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study: NCT00424047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013 plus dexamethasone
Description: 25 mg daily for 21 days every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Placebo
Description: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Study: NCT02134834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP0595
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Study: NCT04184518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Cediranib 20mg, oral, 5 days on and 2 days off until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
Study: NCT03863418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: PROBIOTIC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02370719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for diabetes self-management
Study: NCT02818842

Intervention type: OTHER
Intervention: Primary Health Insurance Fund data
Description: Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date

Intervention type: OTHER
Intervention: Prenatal Diagnostic Center of Toulouse University Hospital data
Description: Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology).

Intervention type: OTHER
Intervention: Mother and child protection data collection
Description: Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)

Intervention type: OTHER
Intervention: Medicalisation Program of Information Systems data
Description: Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)
Study: NCT01760408

Intervention type: OTHER
Intervention: all patients on Home Parenteral Nutrition

Intervention type: OTHER
Intervention: all patients on Home Parenteral Nutrition
Study: NCT03313349

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy: 1. cognitive therapy 2.family intervention
Description: Psychotherapy delivered by trained psychologist for the student and the student´s parents

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy: 1. cognitive therapy 2.family intervention
Description: Psychotherapy delivered by trained psychologist for the student and the student´s parents
Study: NCT03152981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Study: NCT04407806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Pulse oximeter
Description: Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pulse oximeter
Description: Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
Study: NCT03182114

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: supine position
Description: the patient will be placed in regular supine position after spinal anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilted position
Description: the patient will be placed in left lateral tilted position after spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The patient will receive 10 mg Bupivacaine for spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: The patient will receive 10 mg Bupivacaine for spinal anesthesia